A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : IL-2

Search Conditions:
Search Keyword : IL-2
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: IL-2
Appearance Frequency: 13466 time(s)
Long forms: 50

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
interleukin-2
(13402 times)
Allergy and Immunology
(4847 times)
IFN-gamma (1473 times)
NK (1098 times)
TNF-alpha (813 times)
1980 Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line.
cytokines--interleukin 2
(4 times)
Environmental Health
(1 time)
IFN-gamma (3 times)
TNF-alpha (2 times)
Con A (1 time)
1994 Differential nm23 gene expression at the fetal-maternal interface.
interleukin-2 receptor
(4 times)
Orthopedics
(1 time)
ATL (1 time)
BALF (1 time)
DBP (1 time)
1990 Activation antigens in patients with Sjogren's syndrome.
antibody-interleukin 2
(3 times)
Science
(2 times)
EpCAM (1 time)
GM-CSF (1 time)
mGM-CSF (1 time)
1996 Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
interleukin-2 therapy
(3 times)
Neoplasms
(1 time)
ALC (1 time)
CPI (1 time)
irAEs (1 time)
2002 [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
intra-lesional interleukin-2
(3 times)
General Surgery
(3 times)
RECIST (1 time)
2011 Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
DAB389-interleukin-2
(2 times)
Neoplasms
(1 time)
AEs (1 time)
CR (1 time)
CTCL (1 time)
1993 Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells.
IL-2 complex
(2 times)
Microbiology
(1 time)
BM (1 time)
BMT (1 time)
HSV-1 (1 time)
2016 IL-2/alpha-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment.
interleukin-2 levels
(2 times)
Biochemistry
(2 times)
I-V (1 time)
OMP (1 time)
P. mirabilis (1 time)
1998 Chromatin remodeling of the interleukin-2 gene: distinct alterations in the proximal versus distal enhancer regions.
10  A-induced lymphoproliferation, interleukin-2
(1 time)
Allergy and Immunology
(1 time)
DEX (1 time)
gamma-IFN (1 time)
1993 Dexamethasone suppresses T cell-mediated immunity and enhances disease susceptibility to Eimeria mivati infection.
11  alpha-interleukin 2
(1 time)
Reproductive Medicine
(1 time)
IFN-gamma (1 time)
NK (1 time)
PMA (1 time)
2002 Cytokine production in natural killer cells and lymphocytes in pregnant women compared with women in the follicular phase of the ovarian cycle.
12  anti-CD20-interleukin 2
(1 time)
Hematology
(1 time)
ADCC (1 time)
FACS (1 time)
ICK (1 time)
2005 An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
13  factors-interleukin-2
(1 time)
Pharmacology
(1 time)
2h PBG (1 time)
AST (1 time)
BMI (1 time)
2018 Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients.
14  I-IL-2
(1 time)
Allergy and Immunology
(1 time)
BBB (1 time)
IL (1 time)
Th (1 time)
2004 Permeability of the mouse blood-brain barrier to murine interleukin-2: predominance of a saturable efflux system.
15  IGIFR expression and conversely, exposure of the 2D6
(1 time)
Allergy and Immunology
(1 time)
IGIF (1 time)
IGIFR (1 time)
1997 A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.
16  IL-2 enhanced MLTR
(1 time)
General Surgery
(1 time)
SI (1 time)
1987 [Breast cancer-specific immunity evaluated by a new in vitro method--IL-2 enhanced MLTR].
17  IL-2 mAb
(1 time)
Science
(1 time)
T-regs (1 time)
2006 Selective stimulation of T cell subsets with antibody-cytokine immune complexes.
18  IL-2 MS
(1 time)
Neurosurgery
(1 time)
--- 2003 Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
19  IL-2 on induction of lymphokine
(1 time)
Neoplasms
(1 time)
KHF (1 time)
s.c (1 time)
1989 Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
20  IL-2 priming
(1 time)
Neoplasms
(1 time)
MSC (1 time)
2015 Transcriptional profiling of interleukin-2-primed human adipose derived mesenchymal stem cells revealed dramatic changes in stem cells response imposed by replicative senescence.
21  IL-2 receptor
(1 time)
Neoplasms
(1 time)
Ts (1 time)
1991 Suppressor function of lymphocytes activated in in vitro co-culture against autologous tumor cells and expanded in interleukin-2.
22  IL-2 Site7
(1 time)
Allergy and Immunology
(1 time)
--- 2013 Methylation of IL-2 promoter at birth alters the risk of asthma exacerbations during childhood.
23  IL-2 solution
(1 time)
Allergy and Immunology
(1 time)
DC (1 time)
IL-2 micelle (1 time)
2014 Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs.
24  IL-2, GM-CSF and TNF-alpha, and at least one of them
(1 time)
Allergy and Immunology
(1 time)
PWM (1 time)
PWM-RBC (1 time)
1993 Human T lymphocyte activation by pokeweed mitogen induces production of TNF-alpha and GM-CSF and helper signaling by IL-1 and IL-6 results in IL-2-dependent T cell growth.
25  IL-2-L
(1 time)
Allergy and Immunology
(1 time)
--- 1988 The construction and characterization of a biologically active recombinant IL-2 containing a lysine-rich C-terminal extension.
26  IL-2-producing cells
(1 time)
Allergy and Immunology
(1 time)
CTL-P (1 time)
MLC (1 time)
SC (1 time)
1988 Dynamics of cytotoxic T lymphocyte precursors in vivo assessed by change in the radiation sensitivity. Evidence for development of radiation-sensitive memory cells without clonal expansion.
27  IL-2: or TNF immunotherapy
(1 time)
Health Services
(1 time)
NO (1 time)
TNF (1 time)
1996 Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
28  IL-2Lys20
(1 time)
Neoplasms
(1 time)
--- 1991 Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA.
29  IL-2MAB602
(1 time)
Neoplasms
(1 time)
IL-12 (1 time)
2015 Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.
30  IL-2R alpha, IL-2R beta-chain
(1 time)
Transplantation
(1 time)
--- 2000 Quantitative flow cytometry to measure the TNF-alpha and IL-2 system after heart transplantation.
31  IL-2R gamma
(1 time)
Allergy and Immunology
(1 time)
SCID (1 time)
1996 Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: selective induction of anti-apoptotic (bcl-2, bcl-xL) but not pro-apoptotic (bax, bcl-xS) gene expression.
32  Il-2rgamma
(1 time)
Medicine
(1 time)
FAH (1 time)
HBV (1 time)
HCV (1 time)
2010 Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment.
33  in vitro long-term interleukin-2
(1 time)
Allergy and Immunology
(1 time)
mAb (1 time)
NK (1 time)
VCAM-1 (1 time)
1996 Expression and function of alpha 4/beta 7 integrin on human natural killer cells.
34  including lectins, interleukin-2
(1 time)
Allergy and Immunology
(1 time)
mAbs (1 time)
PHA (1 time)
1989 Potentiation of interleukin-2 production and its binding by monoclonal antibodies to the gangliosides GD3 and GD2.
35  including tumor necrosis factor (TNF-alpha),interleukin-2
(1 time)
Physiology
(1 time)
COS (1 time)
FGSCs (1 time)
MVH (1 time)
2017 [Effects of COS on promoting the pathological ovarian aging mice ovarian function by regulating immune function].
36  inflammatory factor-2
(1 time)
Neoplasms
(1 time)
CD31 (1 time)
EOC (1 time)
ITGbeta1 (1 time)
2018 Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
37  interleukin-2 and -6
(1 time)
Psychopharmacology
(1 time)
HC (1 time)
PANSS (1 time)
SCH (1 time)
2009 Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
38  interleukin-2 antagonists
(1 time)
Transplantation
(1 time)
AZA (1 time)
MMF (1 time)
2008 Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation.
39  interleukin-2 heterozygous
(1 time)
Allergy and Immunology
(1 time)
DSS (1 time)
2005 Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse.
40  interleukin-2 proteins
(1 time)
Allergy and Immunology
(1 time)
NK (1 time)
PBMC (1 time)
1985 Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2.
41  interleukin-2-activated
(1 time)
Allergy and Immunology
(1 time)
PRV (1 time)
SLA (1 time)
1997 Establishment and characterization of porcine cytolytic cell lines and clones.
42  Interleukin-2/T-cell growth factor
(1 time)
Pharmacology
(1 time)
CTL (1 time)
1985 Modulation of in vitro cellular immune response by histamine agonists or antagonists in murine species.
43  interleukins 2, 6 and 8
(1 time)
Pulmonary Medicine
(1 time)
IFN-gamma (1 time)
IL-12 (1 time)
TNF-alpha (1 time)
1995 Functions of T-cell subsets and cytokines in mycobacterial infections.
44  intraperitoneally every 12 hours for 28 days; group IB
(1 time)
General Surgery
(1 time)
LAK (1 time)
1990 Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
45  intraperitoneally with PBMC+Interleukin-2
(1 time)
Neoplasms
(1 time)
NK (1 time)
2016 Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
46  ISIL in 20% PDLG
(1 time)
Biochemistry
(1 time)
ISFI (1 time)
ISILs (1 time)
NMP (1 time)
2012 A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery.
47  PHA-induced lymphokine--interleukin 2
(1 time)
Allergy and Immunology
(1 time)
IFN-gamma (1 time)
mAbs (1 time)
PMNC (1 time)
1988 Fenoterol effects on the in vitro immune response.
48  PspA-interleukin-2
(1 time)
Allergy and Immunology
(1 time)
GM-CSF (1 time)
IgG1 (1 time)
PspA (1 time)
1998 Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.
49  ribavirin-interleukin-2
(1 time)
Gastroenterology
(1 time)
HCV (1 time)
IFN-alpha (1 time)
2006 Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1.
50  scFv-Fc-interleukin 2
(1 time)
Pharmacology
(1 time)
ADCC (1 time)
2007 Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.